Viemed Healthcare (NASDAQ:VMD) Upgraded to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Viemed Healthcare (NASDAQ:VMD) from a buy rating to a strong-buy rating in a report published on Saturday,Wall Street Zen reports.

Other analysts also recently issued research reports about the company. Weiss Ratings downgraded Viemed Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, August 17th. Freedom Capital downgraded Viemed Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 5th. Finally, Barrington Research initiated coverage on Viemed Healthcare in a report on Monday, August 24th. They issued an “outperform” rating and a $14.00 target price for the company. One analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $14.00.

Viemed Healthcare Stock Performance

Shares of VMD opened at $9.13 on Friday. The firm has a market cap of $345.94 million, a price-to-earnings ratio of 24.03, a price-to-earnings-growth ratio of 2.21 and a beta of 1.05. The company’s fifty day moving average is $9.26 and its 200-day moving average is $9.59. The company has a quick ratio of 1.02, a current ratio of 1.25 and a debt-to-equity ratio of 0.05. Viemed Healthcare has a 12 month low of $6.18 and a 12 month high of $12.61.

Viemed Healthcare (NASDAQ:VMD) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.01). The business had revenue of $80.67 million during the quarter, compared to analyst estimates of $80.78 million. Viemed Healthcare had a net margin of 5.03% and a return on equity of 10.64%. Equities analysts expect that Viemed Healthcare will post 0.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of VMD. Renaissance Technologies LLC increased its holdings in shares of Viemed Healthcare by 0.3% in the first quarter. Renaissance Technologies LLC now owns 442,200 shares of the company’s stock valued at $4,073,000 after purchasing an additional 1,400 shares in the last quarter. State of Alaska Department of Revenue lifted its holdings in Viemed Healthcare by 49.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 5,145 shares of the company’s stock worth $46,000 after buying an additional 1,711 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Viemed Healthcare by 2.2% during the 1st quarter. Bank of New York Mellon Corp now owns 81,326 shares of the company’s stock worth $749,000 after buying an additional 1,773 shares in the last quarter. Signaturefd LLC boosted its position in Viemed Healthcare by 64.0% in the 3rd quarter. Signaturefd LLC now owns 4,939 shares of the company’s stock valued at $45,000 after buying an additional 1,927 shares during the last quarter. Finally, Covestor Ltd bought a new position in Viemed Healthcare in the 3rd quarter valued at $28,000. Institutional investors and hedge funds own 74.24% of the company’s stock.

About Viemed Healthcare

Viemed Healthcare, Inc (NASDAQ: VMD) is a U.S. healthcare company that provides in-home medical equipment and clinical services for patients with chronic respiratory and other complex medical conditions. Its services are designed to help patients receive care at home while supporting hospitals and clinicians in managing ongoing conditions.

The company’s offerings include non-invasive ventilation, oxygen therapy, sleep-apnea equipment, respiratory therapy, remote patient monitoring and related durable medical equipment.